Novo Nordisk A/S (0QIU.IL)
| Previous close | 974.45 |
| Open | 982.90 |
| Bid | 1,011.40 x 0 |
| Ask | 997.60 x 0 |
| Day's range | 966.00 - 982.90 |
| 52-week range | 86.66 - 1,032.20 |
| Volume | |
| Avg. volume | 615,651 |
| Market cap | 4.107T |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 65.82 |
| EPS (TTM) | 14.86 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | 7.08 (1.04%) |
| Ex-dividend date | 18 Aug 2023 |
| 1y target est | N/A |
Investor's Business DailyCopper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Southern Copper and gold stock Agnico eagle surged above early buy points on hopeful signs for U.S. and China policy.
ReutersNovo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector
Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022. The UK industry body Prescription Medicines Code of Practice Authority (PMCPA) said on Friday that the reprimand followed a voluntary submission by Novo about the payments, which related to more than 150 different bodies and included fees and expenses to health professionals and sponsorship and other payments to healthcare organisations.
ZacksNVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
